Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
| ▸ | GALR1 | P47211 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL525732 | 0.83 | ALOX15 (0.42) | CHRNB4CHRNA3MAOBBRD4ALDH1A1 | |
| SCHEMBL525420 | 0.83 | EGFR (0.43) | CHRNB4CHRNA3MAOAMAOBALDH1A1 | |
| SCHEMBL525548 | 0.83 | KDM4E (0.38) | CHRNB4CHRNA3MAOAMAOBGALR1 | |
| SCHEMBL525198 | 0.83 | MAPT (0.36) | CHRNB4CHRNA3MAOAMAOBGALR1 | |
| SCHEMBL524806 | 0.80 | TGFBR1 (0.34) | ALDH1A1SMN1; SMN2PIM1PIM3 | |
| SCHEMBL525555 | 0.80 | BRD4 (0.52) | MAOBBRD4ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL525411 | 0.80 | PIM1 (0.46) | MAOBBRD4GALR1ALDH1A1PIM1 | |
| SCHEMBL631629 | 0.79 | TDP2 (0.44) | MAOAMAOBALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL525730 | 0.76 | SRC (0.43) | BRD4ALDH1A1 | |
| SCHEMBL525293 | 0.76 | HSD17B1 (0.39) | BRD4ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315482-B2 | Derivatives useful as antiviral agents | INSTITUT PASTEUR (FR) | 2016-04-19 | — | — | US | claimed |
| US-20130210886-A1 | Novel Derivatives Useful as Antiviral Agents | INSTITUT PASTEUR (FR) | 2013-08-15 | — | — | US | claimed |
| EP-2598495-A1 | NOVEL DERIVATIVES USEFUL AS ANTIVIRAL AGENTS | Institut Pasteur (FR) | 2013-06-05 | — | — | EP | claimed |
| EP-2420495-A1 | Novel derivatives useful as antiviral agents | Institut Pasteur (FR) | 2012-02-22 | — | — | EP | claimed |
| WO-2012014181-A1 | NOVEL DERIVATIVES USEFUL AS ANTIVIRAL AGENTS | INSTITUT PASTEUR (FR) | 2012-02-02 | — | — | WO | claimed |
| US-9315482-B2 | Derivatives useful as antiviral agents | INSTITUT PASTEUR (FR) | 2016-04-19 | — | — | US | disclosed |
| US-20130210886-A1 | Novel Derivatives Useful as Antiviral Agents | INSTITUT PASTEUR (FR) | 2013-08-15 | — | — | US | disclosed |
| EP-2598495-A1 | NOVEL DERIVATIVES USEFUL AS ANTIVIRAL AGENTS | Institut Pasteur (FR) | 2013-06-05 | — | — | EP | disclosed |
| EP-2420495-A1 | Novel derivatives useful as antiviral agents | Institut Pasteur (FR) | 2012-02-22 | — | — | EP | disclosed |
| WO-2012014181-A1 | NOVEL DERIVATIVES USEFUL AS ANTIVIRAL AGENTS | INSTITUT PASTEUR (FR) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210886-A1 | Novel Derivatives Useful as Antiviral Agents | MAVS, IRF3, IFNAR1 | CHRNB4 4773/4885CHRNA3 4732/4885MAOA 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.